Personalized Medicine – why the sudden popularity?

Posted by cdavenport on Thursday Nov 12, 2009 Under Blog, Personalized medicine

The dream of tailor-made medication is not a new one, but the prospective cost of such treatments has always been a barrier to growth.  Simply put, the return on compounds that only treat small populations cannot justify the investment.  With life expectancy increasing and the cost of health care rising, however, an economic imperative is driving the change from managing sickness to managing wellness.   A wellness-management approach detects conditions early, and hence the level of reversibility is high;  the current reactive model has lower reversibility.  With drugs targeted toward specific populations, the importance  and acceptance of in silico modeling would increase.  The author presumes that drug development programs will run more quickly, and that regulatory bodies would be able to approve drugs much earlier once a response in the target population has been proven.  This is anticipated to reduce the clinical development time line and lead to cheaper drugs and prolonged exclusivity.

With the trend towards a lower acceptance of risk and thus bigger and more expensive clinical trials, do you agree with the author’s assumptions, especially given a smaller target population?

Source:  Drug Discovery and Development

Be Sociable, Share!

One Response to “Personalized Medicine – why the sudden popularity?”

  1. bindhu michael Says:

    hate to be cliche, but it must be about the money!

    Below is an excerpt from New Development in the race for cheap and fast genome sequencing – see details at [http://www.futuremedicine.com/doi/full/10.2217/pme.09.46|leo://plh/http%3A*3*3www%2Efuturemedicine%2Ecom*3doi*3full*310%2E2217*3pme%2E09%2E46/cP2Z?_t=tracking_disc ]

    A new DNA sequencing technology by Pacific Biosciences (CA, USA) called single molecule real-time (SMRT) sequencing, due to be commercially released in 2010, is expected to increase the speed of genome sequencing and very economical (hoped to achieve a price tag of US$100 per genome and be able to sequence DNA 20,000 times faster than second-generation sequencers that are currently available on the market). They quote the original source as 2009 Industrial Physics Forum Annual Meeting: [http://www.aapm.org/meetings/09AM/IPForum.asp|leo://plh/http%3A*3*3www%2Eaapm%2Eorg*3meetings*309AM*3IPForum%2Easp/yHcs?_t=tracking_disc ]

    Pretty good amount of information in wikipedia (Yes, it is not a peer-reviewed journal, but it is a good for an overall review for those, and they give lots of references one can check out): [http://en.wikipedia.org/wiki/Personalized_medicine|leo://plh/http%3A*3*3en%2Ewikipedia%2Eorg*3wiki*3Personalized_medicine/YYCP?_t=tracking_disc ]

    Another one-stop resource: Personalized medicine, a journal by the future medicine group. [http://www.futuremedicine.com/loi/pme|leo://plh/http%3A*3*3www%2Efuturemedicine%2Ecom*3loi*3pme/V30f?_t=tracking_disc ]

    Does politics have anything to do with the popularity of personalized medicine?

    See “A new President, a new Congress and the path to personalized medicine by Robert Wells: Personalized Medicine, May 2009, Vol. 6, No. 3, Pages 235-239. http://www.futuremedicine.com/doi/full/10.2217/pme.09.7

    Latest News & Updates from the Personalized Medicine Coalition, Edward Abrahams in Personalized Medicine, May 2009, Vol. 6, No. 3, Pages 245-245
    http://www.futuremedicine.com/doi/full/10.2217/pme.09.16

    Quote from this:

    “The infrastructure of laws, policy, education and clinical practice is being built around personalized medicine to support its use:

    ▪ Medical institutions and governments around the world have announced their commitment to putting personalized medicine into practice through dedicated centers or state-wide initiatives.

    ▪ Personalized medicine approaches are becoming ‘best practice’ in hospitals, in order to guarantee that patients with serious conditions, such as cancer, are given optimum therapy from the start.

    ▪ The regulatory system in the USA is integrating genetic testing into the labels of pharmaceutical products, ensuring that a drug is administered in a way that minimizes the risk of adverse effects and improves the chances of effective treatment.

    ▪ Nearly every major pharmaceutical development project is incorporating information on genetic variation and its effects on the safety and effectiveness of the candidate drug.

    ▪ Leading medical schools in the USA and elsewhere are launching genomics-based medical education programs to train the next generation of care providers.

    ▪ Personalized medicine applications have extended beyond cancer to improve treatments in cardiovascular disease, infectious diseases, psychiatric disorders, and transplantation medicine.”

    Here are many more insightful articles in Personalized Medicine, with free access:

    Living with my personal genome by none other than Jim Watson: Personalized Medicine, November 2009, Vol. 6, No. 6, Pages 607-607
    http://www.futuremedicine.com/doi/full/10.2217/pme.09.62

    The biomarker revolution: a step toward personalized medicine by Jean-Yves Bonnefoy in Personalized Medicine, November 2008, Vol. 5, No. 6, Pages 553-556. http://www.futuremedicine.com/doi/full/10.2217/17410541.5.6.553

    What are the stakes? Genetic nondiscrimination legislation and personal genomics by Barbara Prainsack in Personalized Medicine, September 2008, Vol. 5, No. 5, Pages 415-418
    http://www.futuremedicine.com/doi/full/10.2217/17410541.5.5.415

    1000 Genomes: on the road to personalized medicine by Amy L McGuire in Personalized Medicine, May 2008, Vol. 5, No. 3, Pages 195-197
    http://www.futuremedicine.com/doi/full/10.2217/17410541.5.3.195

    Direct-to-consumer genetic testing in the age of personalized medicine by Pascal Borry in Personalized Medicine, November 2009, Vol. 6, No. 6, Pages 617-619. http://www.futuremedicine.com/doi/full/10.2217/pme.09.61

    ‘Private fears in public places?’ Ethical and regulatory concerns regarding human genomic databases” by Barbara Prainsack & David Gurwitz in Personalized Medicine, November 2007, Vol. 4, No. 4, Pages 447-452
    http://www.futuremedicine.com/doi/full/10.2217/17410541.4.4.447

    The right prescription for personalized genetic medicine by Gail H Javitt & Kathy Hudson in Personalized Medicine, May 2007, Vol. 4, No. 2, Pages 115-118. http://www.futuremedicine.com/doi/full/10.2217/17410541.4.2.115

    Medicine, genetics and race: the case of cardiovascular diseases by Jose M Ordovas in Personalized Medicine, February 2007, Vol. 4, No. 1, Pages 1-6 ,
    http://www.futuremedicine.com/doi/full/10.2217/17410541.4.1.1

    “Beyond personalized medicine” by Claus Møldrup in Personalized Medicine, May 2009, Vol. 6, No. 3, Pages 231-233.
    http://www.futuremedicine.com/doi/full/10.2217/pme.09.10

    “Interview: Advancing personalized medicine to improve health outcomes” by Amalia Issa in Personalized Medicine, May 2009, Vol. 6, No. 3, Pages 251-254. http://www.futuremedicine.com/doi/full/10.2217/pme.09.15

    Personalized medicine for breast cancer: moving forward and going back
    Jeffrey S Ross, W Fraser Symmans, Lajos Pusztai & Gabriel N Hortobagyi in Personalized Medicine, November 2006, Vol. 3, No. 4, Pages 363-370
    http://www.futuremedicine.com/doi/full/10.2217/17410541.3.4.363

    Personalized immunotherapy: a siren myth? by Antoine Tesniere, Guido Kroemer,Thomas Tursz and Laurence Zitvogel in Personalized Medicine
    September 2009, Vol. 6, No. 5, Pages 469-473
    http://www.futuremedicine.com/doi/full/10.2217/pme.09.39

    Fintan R Steele’s article “Personalized medicine: something old, something new” in Personalized Medicine, January 2009, Vol. 6, No. 1, Pages 1-5. http://www.futuremedicine.com/doi/full/10.2217/17410541.6.1.1

    More resources of interest:

    personalized medicine coalition has a link to their report on The Case for Personalized Medicine, Second Edition. http://www.personalizedmedicinecoalition.org/communications/pmc_pub_5_09.php

    http://www.pgxnews.org/web/ gives updates about advances in Pharmacogenomics and Personalized Medicine

    Why would drugmakers want tests that reveal that some people won’t be helped by their drugs?

    In “The Era of Personalized Medicine by Katherine Hobson”, Edward Abrahams answers this as follows: ” That used to be a common view, but no longer. Drug companies have come to understand that putting safer and more efficacious drugs on the market serves their interests more than failed drugs, and they’ve embraced the principles of personalized medicine. There have been any number of drugs withdrawn from the market because of adverse events for a small minority of people. If you knew [who’d suffer side effects] in advance, that could be avoided.” http://www.ihavenet.com/Health-Era-of-Personalized-Medicine-Edward-Abrahams.html

    The Coriell Personalized Medicine Collaborative (a longitudinal research study designed to determine the utility of using personal genome information in health management and clinical decision-making.) is enrolling individuals in a research study to investigate the impact of personalized medicine on health outcomes. http://cpmc.coriell.org/

    S. 976 [110th]: Genomics and Personalized Medicine Act of 2007 in the US senate. http://www.govtrack.us/congress/billtext.xpd?bill=s110-976

    Check out FDA’s national center for toxicological research’s division for Personalized Nutrition and Medicine (Director: James A. Kaput, Ph.D.)
    http://www.fda.gov/AboutFDA/CentersOffices/nctr/WhatWeDo/ResearchDivisions/ucm079056.htm

    A non-academic thought: Don’t we live in an era where speed and individuality matters more than ever? Every other technology is using the personalized approach (mobile phones and other electronic gadgets to food). So may be “the time has come” for medicine also to be personalized more than ever before!

Leave a Reply